Clinical Trial Update: A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase II study evaluating daily sorafenib in combination with repeated 21-day cycles of dacarbazine in patients with advanced/metastatic melanoma; results have …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• DTIC-Dome (dacarbazine)
• Nexavar (Sorafenib)

Snippet

Sponsor: Bayer | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2011-01-25